Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

SML3069

Sigma-Aldrich

NVP-2

≥98% (HPLC)

Sinônimo(s):

4-[[[5′-Chloro-2′-[[trans-4-[[(1R)-2-methoxy-1-methylethyl]amino]cyclohexyl]amino][2,4′-bipyridin]-6-yl]amino]methyl]tetrahydro-2H-pyran-4-carbonitrile, NVP2

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C27H37ClN6O2
Número CAS:
Peso molecular:
513.07
Código UNSPSC:
12352200
NACRES:
NA.77

Nível de qualidade

Ensaio

≥98% (HPLC)

forma

powder

cor

white to brown

solubilidade

DMSO: 2 mg/mL, clear

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

C[C@H](COC)N[C@@H]1CC[C@@H](NC2=NC=C(Cl)C(C3=NC(NCC4(CCOCC4)[N+]#[C-])=CC=C3)=C2)CC1

Ações bioquímicas/fisiológicas

NVP-2 is an ATP-competitive, highly potent and selective cyclin-dependent kinase CDK9 inhibitor (human Cdk9/CycT1 IC50 = 0.3 nM with 6 μM ATP; DYRK1B IC50 = 350 nM; CDK7 IC50 >10 ?M; 0-63% inhibition of 366 other kinases at 1 μM, including CDK2/3/4/5/8). NVP-2 inhibits RNA Pol II-mediated transcription by blocking Cdk9-dependent RNA Pol II CTD phosphorylation (250 nM for 1-24 hrs; MOLT4 cells), displaying higher apoptosis-inducing and antiproliferation efficacy than the CDK2/7/9 inhibitor SNS-032 (BMS-387032) in leukemia cultures (MOLT4 IC50 = 9 nM/NVP-2 vs. 173 nM/SNS-032).

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Phillip Wright et al.
Archives of toxicology, 93(3), 659-671 (2019-01-09)
Cyclin-dependent kinases (CDKs) are a family of kinases associated predominantly with cell cycle control, making CDK inhibitors interesting candidates for anti-cancer therapeutics. However, retinal toxicity (loss of photoreceptors) has been associated with CDK inhibitors, including the pan-CDK inhibitor AG-012896. The
Matthias Muhar et al.
Science (New York, N.Y.), 360(6390), 800-805 (2018-04-07)
Defining direct targets of transcription factors and regulatory pathways is key to understanding their roles in physiology and disease. We combined SLAM-seq [thiol(SH)-linked alkylation for the metabolic sequencing of RNA], a method for direct quantification of newly synthesized messenger RNAs
Yang Gao et al.
Cell chemical biology, 25(2), 135-142 (2017-12-26)
Irreversible inhibition of transcriptional cyclin-dependent kinases (CDKs) provides a therapeutic strategy for cancers that rely on aberrant transcription; however, lack of understanding of resistance mechanisms to these agents will likely impede their clinical evolution. Here, we demonstrate upregulation of multidrug
Georg E Winter et al.
Molecular cell, 67(1), 5-18 (2017-07-05)
Processive elongation of RNA Polymerase II from a proximal promoter paused state is a rate-limiting event in human gene control. A small number of regulatory factors influence transcription elongation on a global scale. Prior research using small-molecule BET bromodomain inhibitors
Calla M Olson et al.
Nature chemical biology, 14(2), 163-170 (2017-12-19)
Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica